EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients

Dvora Frankenthal iD, Miri Zatlawi iD, Ziv Karni-Efrati, Lital Keinan-Boker, Aharona Glatman-Freedman, Michal Bromberg

PLOS One · 2025

DOI: 10.1371/journal.pone.0326231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Dvora Frankenthal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health, The Israel Center for Disease Control, Ramat Gan, Israel. Hauptthemen laut MEDLINE: COVID-19, Immunization, Secondary, COVID-19 Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Periodic vaccination against COVID-19 persists with a recommendation to vaccinate especially older people and the chronically ill. However, vaccination compliance is low, likely due to concerns regarding adverse events (AEs).

Objective

To systematically and proactively evaluate the occurrence, onset, duration, and severity of self-reported AEs and comorbidities exacerbations that appeared up to 21–30 days following the third (booster) Pfizer BNT162b2 vaccine dose, and to examine the associations between the occurrence of any AEs and sociodemographic and pre-existing comorbidities.

Methods

A cross-sectional telephone survey among a nationally representative sample of Israeli vaccinated adults aged ≥18 was conducted from September through October 2021. Sociodemographic data was extracted from the Ministry of Health vaccination database, and data on AEs and comorbidities were collected using a structured questionnaire.

Results

Overall, 2,049 participants completed the survey (71.4% response rate). A total of 1360 (66.4%) reported at least one AE following the booster vaccine. The most frequently reported AEs were local (55.7%) and mild systemic (48.6%) reactions (i.e., fatigue, headache, fever), followed by neurological (4.5%) and allergic (3.9%) reactions. Exacerbation of comorbidities following the booster dose was most frequently reported by individuals with autoimmune or mental conditions. Most local (80.1%) and systemic (69.5%) reactions lasted up to three days. Only 8.3% sought medical care. Menstrual changes were reported by 9.6% of women aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Immunization, SecondaryCOVID-19 VaccinesHumansFemaleMaleMiddle AgedAdultCross-Sectional StudiesAgedComorbidityAdolescentYoung AdultIsraelSARS-CoV-2Surveys and QuestionnairesBNT162 VaccineVaccination

Substanzen

COVID-19 VaccinesBNT162 Vaccine

Autor:innen und Institutionen

  • Ministry of Health, The Israel Center for Disease Control, Ramat Gan, Israel.
  • Center for Research and Study of Aging, University of Haifa, Haifa, Israel.
  • School of Public Health, University of Haifa, Haifa, Israel.
  • The school of Public Health, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Dvora Frankenthal, Miri Zatlawi

Zitieren

APA

Frankenthal, D., Zatlawi, M., Karni-Efrati, Z., Keinan-Boker, L., Glatman-Freedman, A., & Bromberg, M. (2025). Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients. PLOS One. https://doi.org/10.1371/journal.pone.0326231

Vancouver

Frankenthal D, Zatlawi M, Karni-Efrati Z, Keinan-Boker L, Glatman-Freedman A, Bromberg M. Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients. PLOS One. 2025. doi:10.1371/journal.pone.0326231

BibTeX
@article{Frankenthal2025,
  author = {Frankenthal, Dvora and Zatlawi, Miri and Karni-Efrati, Ziv and Keinan-Boker, Lital and Glatman-Freedman, Aharona and Bromberg, Michal},
  title = {Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326231}
}
Kostenlos starten →